S. Contributors and . Lp-b, LDA are involved in clinical study design, critical review of the manuscript and final approval of the manuscript; CI is responsible for clinical study design and final approval of the manuscript

C. Merck, . Pharma, . Ferring, M. Cellerix, . Takeda et al., AD has served as a speaker and consultant for Ferring, EL has received fees for: Educational Grant: MSD, Abbvie

. Abbvie, . Ferring, . Msd, M. Takeda, . Pharma-abbvie et al., Prometheus laboratories/Nestle, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor, and received speaker fees from ID has served as a speaker and consultant for Ferring, and Given Imaging. GR has served as a speaker and consultant for Abbvie Vital Solutions, and Vifor, Zeller. LDA is an employee of Ferring. CI has served as biostatistician consultant for Roche, LPB has received consulting fees from Merck Index Pharmaceuticals, Amgen, and Sandoz; Lecture fees from Merck, pp.and HAC-pharma

R. Eliakim and F. Magro, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis, J Crohns Colitis, vol.6, pp.965-90, 2012.

J. Burisch, J. T. Martinato, and M. , The burden of inflammatory bowel disease in Europe, Journal of Crohn's and Colitis, vol.7, issue.4, pp.322-329, 2013.
DOI : 10.1016/j.crohns.2013.01.010

R. Cohen, A. Yu, and E. Wu, Systematic review: the costs of ulcerative colitis in Western countries, Alimentary Pharmacology & Therapeutics, vol.11, issue.7 Suppl A, pp.693-707, 2010.
DOI : 10.1155/1988/654517

S. Lönnfors, S. Vermeire, and M. Greco, IBD and health-related quality of life ??? Discovering the true impact, Journal of Crohn's and Colitis, vol.8, issue.10, pp.1281-1287, 2014.
DOI : 10.1016/j.crohns.2014.03.005

S. Ghosh and R. Mitchell, Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn???s and Ulcerative Colitis Associations (EFCCA) patient survey, Journal of Crohn's and Colitis, vol.1, issue.1, pp.10-20, 2007.
DOI : 10.1016/j.crohns.2007.06.005

A. Dignass, J. Lindsay, and A. Sturm, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management, Journal of Crohn's and Colitis, vol.6, issue.10, pp.991-1030, 2012.
DOI : 10.1016/j.crohns.2012.09.002

G. Lichtenstein, M. Abreu, and R. Cohen, American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease, Gastroenterology, vol.130, issue.3, pp.940-87, 2006.
DOI : 10.1053/j.gastro.2006.01.048

S. Travis, E. Strange, and M. Lémann, European evidence based consensus on the diagnosis and management of Crohn's disease: current management, Gut, vol.55, issue.suppl_1, pp.16-35, 2006.
DOI : 10.1136/gut.2005.081950b

U. Actavis and . Ltd, Prednisolone Gastro-resistant Tablets Summary of Product Characteristics, 2016.

C. Teshima and R. Fedorak, Are there differences in type, dosage, and method of administration for the systemic steroids in IBD treatment?, Inflammatory Bowel Diseases, vol.14, issue.2, pp.216-234, 2008.
DOI : 10.1002/ibd.20728

S. Katz, The practical use of corticosteroids in the treatment of inflammatory bowel disease, Pract Gastroenterol, vol.29, pp.14-25, 2005.

E. Schoon, S. Bollani, and P. Mills, Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn???s disease, Clinical Gastroenterology and Hepatology, vol.3, issue.2, pp.113-134, 2005.
DOI : 10.1016/S1542-3565(04)00662-7

F. Dr, U. Pharma, and . Ltd, Budenofalk® Summary of Product Characteristics, 2016.

U. Astrazeneca and . Ltd, Entocort® EC Summary of Product Characteristics, 2016.

M. Brunner, S. Ziegler, D. Stefano, and A. , Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation, British Journal of Clinical Pharmacology, vol.40, issue.3, pp.31-37, 2006.
DOI : 10.1677/joe.0.1780339

L. Ferring-pharmaceuticals, Cortiment® Summary of Product Characteristics, 2016.

W. Sandborn, S. Travis, and L. Moro, Once-Daily Budesonide MMX?? Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study, Gastroenterology, vol.143, issue.5, pp.1218-1244, 2012.
DOI : 10.1053/j.gastro.2012.08.003

S. Travis, S. Danese, and L. Kupcinskas, Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study, Gut, vol.142, issue.Suppl 1, pp.433-474, 2014.
DOI : 10.1016/S0016-5085(12)63046-7

W. Sandborn, S. Danese, D. Haens, and G. , Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9??mg: pooled analysis of two phase 3 studies, Alimentary Pharmacology & Therapeutics, vol.39, issue.5, pp.409-427, 2015.
DOI : 10.1111/apt.12712

D. Rubin, R. Cohen, and W. Sandborn, Budesonide MMX® 9 mg for inducing remission in patients with mild-to-moderate ulcerative colitis not adequately controlled with oral 5-ASAs, J Crohns Colitis, vol.9, p.7, 2015.

G. Lichtenstein, S. Travis, and S. Danese, Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis, Journal of Crohn's and Colitis, vol.9, issue.9, pp.738-784, 2015.
DOI : 10.1093/ecco-jcc/jjv101

C. Ha, T. Ullman, and C. Siegel, Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population, Clinical Gastroenterology and Hepatology, vol.10, issue.9, pp.1002-1009, 2012.
DOI : 10.1016/j.cgh.2012.02.004

J. Salleron, S. Danese, D. Agay, and L. , Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge, Journal of Crohn's and Colitis, vol.10, issue.9, p.68, 2016.
DOI : 10.1093/ecco-jcc/jjw068

URL : https://hal.archives-ouvertes.fr/hal-01662135

S. Danese, C. Siegel, and L. Peyrin-biroulet, Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.63, issue.Suppl. 1, pp.1095-103, 2014.
DOI : 10.1136/gutjnl-2012-304258

N. Williet, W. Sandborn, and L. Peyrin-biroulet, Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.12, issue.8, pp.1246-56, 2014.
DOI : 10.1016/j.cgh.2014.02.016

L. Doward, A. Gnanasakthy, and M. Baker, Patient reported outcomes: looking beyond the label claim, Health and Quality of Life Outcomes, vol.8, issue.1, p.89, 2010.
DOI : 10.1186/1477-7525-8-89

E. Irvine, Q. Zhou, and A. Thompson, The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial, Am J Gastroenterol, vol.91, pp.1571-1579, 1996.

M. Reilly, A. Zbrozek, and E. Dukes, The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument, PharmacoEconomics, vol.4, issue.5, pp.353-65, 1993.
DOI : 10.2165/00019053-199304050-00006

M. Van-der-valk, M. Mangen, and P. Siersema, The Work Productivity and Activity Impairment (WPAI) Questionnaire is a useful tool in patients with ulcerative colitis, Gut, vol.61, p.163, 2012.

R. Brokelman, D. Haverkamp, and C. Van-loon, The validation of the visual analogue scale for patient satisfaction after total hip arthroplasty, European Orthopaedics and Traumatology, vol.79, issue.2, pp.101-106, 2012.
DOI : 10.2106/00004623-199707000-00003

P. Rosenbaum and D. Rubin, The central role of the propensity score in observational studies for causal effects, Biometrika, vol.70, issue.1, pp.41-55, 1983.
DOI : 10.1093/biomet/70.1.41

D. Rubin, Estimating Causal Effects from Large Data Sets Using Propensity Scores, Annals of Internal Medicine, vol.127, issue.8_Part_2, pp.757-63, 1997.
DOI : 10.7326/0003-4819-127-8_Part_2-199710151-00064

D. Price, E. Hillyer, and T. Van-der-molen, Efficacy versus effectiveness trials, Current Opinion in Allergy and Clinical Immunology, vol.13, issue.1, pp.50-57, 2013.
DOI : 10.1097/ACI.0b013e32835ad059

URL : http://pdfs.journals.lww.com/co-allergy/2013/02000/Efficacy_versus_effectiveness_trials___informing.10.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1503044773763;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzdyBLrPxE6SfwpUGO2fXr86s75WO6X3sSuagW0qNkan5g=;hash|ms1kt/FNv/+TQfFCY69dQg==

T. Walters, M. Kim, and L. Denson, Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-?? vs an Immunomodulator in Children With Crohn's Disease, Gastroenterology, vol.146, issue.2, pp.383-91, 2014.
DOI : 10.1053/j.gastro.2013.10.027

M. Kappelman, M. Long, and C. Martin, Evaluation of the Patient-Reported Outcomes Measurement Information System in a Large Cohort of Patients With Inflammatory Bowel Diseases, Clinical Gastroenterology and Hepatology, vol.12, issue.8, pp.1315-1338, 2014.
DOI : 10.1016/j.cgh.2013.10.019